ProCE Banner Activity

How I Use BTK Inhibitors to Treat My Patients With CLL

Clinical Thought
Gain insights for treating patients with CLL with BTK inhibitors in this expert commentary.

Released: April 24, 2020

Expiration: April 23, 2021

Share

Faculty

Ian Flinn

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics AbbVie

Faculty Disclosure

Primary Author

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Ian Flinn, MD, PhD, has disclosed that he has received consulting fees form AbbVie, Seattle Genetics, TG Therapeutics, and Verastem; funds for contracted research from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Merck, Morphosys, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Takeda, Teva, TG Therapeutics, Unum, and Verastem; and he and his spouse have less than 5% ownership interest in Johnson & Johnson.